Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib with Dose-Dense Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT04608409Phase 1Completed
- Start
- Mar 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lapatinib in ovarian cancer (3 arms). Primary endpoints: Progression-free Survival at 1 year and Number of Participants With Dose-limiting Toxicity at 4 weeks. Started Mar 2021; status: completed.
02
Drugs
lapatinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04608409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608409.